Dual-modality imaging combines the complementary advantages of different modalities, and offers the prospect of improved preclinical research. The combination of fluorescence imaging and magnetic resonance imaging (MRI) provides cross-validated information and direct comparison between these modalities. Here, we report on the application of a novel tumor-targeted, dual-labeled nanoparticle (NP), utilizing iron oxide as the MRI contrast agent and near infrared (NIR) dye Cy5.5 as the fluorescent agent. Results of in vitro experiments verified the specificity of the NP to tumor cells. In vivo tumor targeting and uptake of the NPs in a mouse model were visualized by fluorescence and MR imaging collected at different time points. Quantitative analysis was carried out to evaluate the efficacy of MRI contrast enhancement. Furthermore, tomographic images were also acquired using both imaging modalities and cross-validated information of tumor location and size between these two modalities was revealed. The results demonstrate that the use of dual-labeled NPs can facilitate the dual-modal detection of tumors, information cross-validation, and direct comparison by combing fluorescence molecular tomography (FMT) and MRI.
Nano Lett. 2010 Dec 8;10(12):4920-8
[PMID:
21090693]
Oncol Rep. 2009 Jul;22(1):115-9
[PMID:
19513512]
Chem Soc Rev. 2012 Apr 7;41(7):2656-72
[PMID:
22189429]
Neoplasia. 2006 Mar;8(3):214-22
[PMID:
16611415]
Mol Imaging Biol. 2010 Jan-Feb;12(1):25-34
[PMID:
19582510]
Circ Res. 2005 Feb 18;96(3):327-36
[PMID:
15653572]
Cancer Biol Ther. 2010 Jul 15;10(2):166-71
[PMID:
20505368]
ACS Nano. 2012 Apr 24;6(4):3304-10
[PMID:
22443607]
IEEE Trans Med Imaging. 2011 Jun;30(6):1265-73
[PMID:
21317083]
Cancer Res. 2003 Nov 15;63(22):7870-5
[PMID:
14633715]
Eur J Radiol. 2011 Dec;80(3):699-705
[PMID:
20810233]
J Biomed Opt. 2011 Dec;16(12):120511
[PMID:
22191913]
Breast Cancer Res Treat. 2002 Jan;71(1):67-75
[PMID:
11859875]
Cancer Res. 2004 Nov 1;64(21):8009-14
[PMID:
15520209]
Phys Med Biol. 2013 Jan 21;58(2):351-72
[PMID:
23257468]
Annu Int Conf IEEE Eng Med Biol Soc. 2009;2009:1404-7
[PMID:
19964524]
Mol Pharm. 2009 Jul-Aug;6(4):1074-82
[PMID:
19527074]
Opt Lett. 2007 Feb 15;32(4):382-4
[PMID:
17356660]
Nano Lett. 2006 Apr;6(4):669-76
[PMID:
16608262]
J Am Chem Soc. 2011 Dec 7;133(48):19512-23
[PMID:
22029389]
Opt Express. 2007 Dec 24;15(26):18300-17
[PMID:
19551128]
Angiogenesis. 2009;12(1):17-24
[PMID:
19067197]
Circulation. 2007 Mar 20;115(11):1384-91
[PMID:
17339546]
J Nucl Med. 2007 Nov;48(11):1862-70
[PMID:
17942800]
Nat Rev Drug Discov. 2003 Feb;2(2):123-31
[PMID:
12563303]
Eur J Nucl Med Mol Imaging. 2009 Mar;36 Suppl 1:S56-68
[PMID:
19194703]
Clin Cancer Res. 2009 Jul 15;15(14):4722-32
[PMID:
19584158]
J Biomed Opt. 2010 Sep-Oct;15(5):051602
[PMID:
21054076]
AJR Am J Roentgenol. 1989 Jan;152(1):167-73
[PMID:
2783272]
Breast Neoplasms
Carbocyanines
Cell Line, Tumor
Contrast Media
Ferric Compounds
Fluorescent Dyes
Humans
Image Enhancement
Magnetic Resonance Imaging
Microscopy, Fluorescence
Multimodal Imaging
Nanoparticles
Particle Size
Reproducibility of Results
Sensitivity and Specificity
Staining and Labeling
Tomography
